Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Faslodex Registry: a Belgian Observational Study to Evaluate the Use of Fulvestrant in Current Clinical Practice

NCT00735215 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00735215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00735215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Faslodex Registry: a Belgian Observational Study to Evaluate the Use of Fulvestrant in Current Clinical Practice
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 31, 2008
Completion date
December 31, 2009
Enrollment
200 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer